New cancer drug enters first human tests
NCT ID NCT06022250
Summary
This is a first-in-human study to test the safety and find the right dose of an experimental drug called JS207 in people with advanced cancer. It involves 98 patients whose cancer has progressed despite standard treatments. The main goals are to understand the drug's side effects and how the body processes it, which will help plan future studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affiliated Cancer Hospital of Shandong First Medical University
Jinan, Shandong, 250117, China
Conditions
Explore the condition pages connected to this study.